The effect of GnRH-analogue for the treatment of uterine myoma.

概要

論文の詳細を見る
Uterine myoma is the most common pelvic tumor associated with abnormal uterine bleeding, pelvic pain, dysmenorrhea, pregnancy loss and infertility. There are several reports in which gonadotropin -releasing hormone analogue (GnRH-a) have resulted in tumor shrinkage. Clinical trials with GnRH-a consistently have demonstrated efficacy for reducing both myoma size and uterine volume. In this study, 900ug of GnRH-a were daily administered to 80 patients with uterine myoma for 16 weeks. Total symptom severity scores was decreased significantly acording to the shrinkage of uterine volume (the mean decreasing rate was 65.4%). Furthermore, we analyzed the reduction in volume among three types of uterine myoma, intramural type, subserous type and submucous type. As the results, the volume of uterine myoma reduced especially in the intramural and subserous types (the mean reducing rates were 68.0% and 41.4%, respectively), but that did not reduced in the submucous types (the mean reducing rates was 95.8%). The GnRH-a therapy may be useful in those unsuitable for surgery due to other medical problems. More detailed studies are required to establish the most satisfactory treatment regimens related to the myoma types. [Adv Obstet Gynecol 48 (1): 6-11, 1996 (H8.1)]
近畿産科婦人科学会の論文